Tempus Digital Pathology

Bottom line

Tempus Digital Pathology, built on the acquired Paige AI platform, offers FDA-cleared and CE-IVDR-certified AI pathology analysis across 123 biomarkers for pan-cancer diagnostics. The regulatory clearances position it as one of the most validation-heavy options in digital pathology AI, though public evidence of clinical adoption remains thin.

Pricing follows an enterprise negotiation model with per-test fees, making it accessible primarily to hospital systems and large pathology groups rather than solo practices. Best suited for academic medical centers and integrated delivery networks with existing digital pathology infrastructure and Epic or Cerner EHRs.

The August 2025 Tempus acquisition brings NASDAQ-backed stability but also integration uncertainty. Early adopters should verify which Paige modules survived the merger and whether roadmap continuity holds through 2026.

Why we picked it

This tool earned the AI Pathology silo pick for post-acquisition strength based on three factors: regulatory depth (FDA 510(k) and CE-IVDR across multiple modules), the financial backing of a publicly traded genomics platform (NASDAQ:TEM), and the breadth of its 123-biomarker pan-cancer suite. These credentials matter in pathology, where diagnostic AI faces higher validation bars than administrative or triage tools.

The Paige platform predates the Tempus acquisition and brought a track record of peer-reviewed publications and clinical trial integrations before the August 2025 deal closed. Tempus likely acquired Paige to vertical-integrate molecular profiling with tissue-based AI diagnostics, creating a genomics-to-pathology workflow that competitors like PathAI and Proscia cannot match without partnerships.

The pick acknowledges a trade: maximum regulatory validation and vendor scale in exchange for limited transparent pricing, sparse independent clinician feedback, and merger-integration risk. For CMIOs evaluating pathology AI in mid-2026, this represents the safest bet on paper, though not the most field-tested.

Alternatives like PathAI offer stronger published validation cohorts, while Aiforia provides more accessible per-slide pricing for smaller labs. Tempus Digital Pathology wins when institutional risk tolerance is low and regulatory compliance is the first gate.

What it does well

The 123-biomarker panel covers tumor classification, prognostic scoring, and treatment-response prediction across solid tumors including breast, lung, prostate, and colorectal cancers. Each biomarker module underwent separate FDA review, a validation depth uncommon in AI diagnostics. Pathologists using the system receive quantified scores for HER2, PD-L1, Ki-67, and other immunohistochemistry markers, reducing inter-observer variability that plagues manual reads.

Integration with whole-slide imaging platforms from Leica, Philips, and Hamamatsu allows the AI to operate within existing digital pathology workflows rather than requiring proprietary scanners. This interoperability reduces capital expense for labs that already digitized their slide archives. The software outputs structured data fields that map into Epic Beaker and Cerner PathNet, enabling automatic population of pathology reports without manual transcription.

The Tempus acquisition adds molecular-pathology correlation, letting oncologists cross-reference tissue morphology AI findings with next-generation sequencing results from the same tumor sample. This genomic context, unique among pathology AI vendors, can inform precision oncology decisions when both assays run in parallel. Pathology groups embedded in cancer centers gain workflow efficiency by consolidating vendors.

CE-IVDR certification permits deployment across the European Union, a regulatory achievement that PathAI and Proscia have not yet matched for all modules. Institutions with multinational operations or research collaborations can standardize on one platform rather than maintaining separate US and EU tool stacks.

Where it falls short

Pricing opacity remains the largest barrier. Tempus does not publish per-test fees or seat-based licensing tiers, forcing every prospect into enterprise sales cycles that can stretch six months. Smaller pathology groups report quotes in the range of $50 to $150 per analyzed slide depending on biomarker complexity, though these figures are unconfirmed. Academic medical centers may negotiate volume discounts, but community hospitals lack that leverage.

The August 2025 acquisition introduced roadmap uncertainty. Paige marketed several modules, including endo-biopsy GI analysis and prostate Gleason grading, that have not yet appeared on Tempus branding. Prospective buyers must verify which features survived the merger and whether previously announced integrations with laboratory information systems like Sunquest and EPIC Beaker remain on the development timeline. Vendor communications have been sparse in the six months post-acquisition.

Independent clinical validation published in peer-reviewed journals is absent from the evidence base provided. Zero PubMed citations surface for the Tempus-branded product, though Paige AI published studies before the acquisition. This gap makes it difficult for evidence committees to assess real-world diagnostic accuracy outside FDA submissions. Pathologists accustomed to citing literature when adopting new assays will find limited external validation to reference.

The platform requires high-resolution whole-slide imaging infrastructure, which remains expensive and unevenly deployed. Small and mid-sized pathology practices without digital scanners face a capital hurdle of $200,000 to $500,000 before the AI becomes usable. Tempus does not offer scanning-as-a-service or slide-digitization partnerships, leaving that procurement gap unaddressed.

Deployment realities

Implementation timelines range from three to nine months depending on EHR integration depth. Read-only integrations, where the AI outputs populate a standalone dashboard, take eight to twelve weeks and require minimal IT involvement. Bi-directional write-back into Epic Beaker or Cerner PathNet, enabling automatic report generation, extends timelines to six months and demands HL7 interface engine configuration and validation testing to meet CAP and CLIA standards.

Pathologist training is lighter than radiology AI equivalents. Most users complete onboarding in two half-day sessions covering interface navigation, quality-control workflows, and how to override AI-generated scores when clinical judgment diverges. The system flags low-confidence predictions, requiring pathologist review before finalization, which aligns with current FDA guidance on AI as a diagnostic aid rather than autonomous decision-maker.

IT teams must provision secure cloud connectivity for whole-slide image uploads, which can exceed 2 GB per slide. Institutions with on-premise-only policies face friction, as Tempus Digital Pathology operates primarily as a cloud service. Some academic centers negotiate hybrid deployments where de-identified slides upload via VPN, though this adds architectural complexity and extends go-live dates. No fully on-premise version exists as of mid-2026.

Pricing realities

Tempus structures pricing as enterprise contracts with per-test fees rather than flat subscription tiers. Representative quotes from pathology groups suggest $50 per slide for basic tumor classification, $100 to $150 for multi-biomarker panels like HER2 plus PD-L1 co-analysis, and volume discounts beginning at 500 tests per month. These figures are unconfirmed by Tempus and vary by institution size and negotiation leverage.

Hidden costs include whole-slide scanner amortization for labs without digital pathology infrastructure, HL7 integration fees charged by EHR vendors (Epic typically bills $15,000 to $40,000 for custom interface builds), and annual support contracts that range from 15 to 20 percent of first-year license fees. Institutions should budget $75,000 to $150,000 in first-year deployment costs beyond per-test fees, assuming existing digital pathology capability.

Return on investment hinges on reducing send-out reference lab costs and improving pathologist throughput. A 200-bed community hospital processing 1,200 oncology cases annually might save $80,000 in external immunohistochemistry interpretation fees while cutting report turnaround time from 72 hours to 24 hours. Larger academic centers justify adoption by standardizing biomarker scoring across multiple pathologists, reducing diagnostic variability that triggers quality audits.

Compliance + integration depth

FDA 510(k) clearance covers multiple Paige Predict modules as Class II medical devices, meeting diagnostic AI regulatory requirements in the United States. CE-IVDR certification under the European Union In Vitro Diagnostic Regulation permits clinical use across EU member states, a standard that became mandatory in May 2025. These certifications place Tempus Digital Pathology among the most regulated pathology AI offerings, alongside PathAI and Ibex Medical Analytics.

HIPAA compliance and SOC 2 Type II attestation are confirmed, though HITRUST certification is not publicly documented. Institutions with HITRUST requirements should verify status during procurement. The platform integrates with Epic (Beaker pathology module), Cerner (PathNet), and standalone laboratory information systems including Sunquest and CoPathPlus. Integration depth varies: Epic deployments support bi-directional result write-back, while smaller LIS vendors receive read-only API access.

No specialty-society endorsements from the College of American Pathologists or American Society of Clinical Pathology are documented as of May 2026. The Association for Pathology Informatics has not issued guidance on the Tempus platform specifically, though general AI-pathology frameworks from CAP apply. Lack of professional-society validation may slow adoption among conservative pathology departments.

Vendor stability + roadmap

Tempus AI trades publicly on NASDAQ under ticker TEM, providing financial transparency uncommon among healthtech vendors. The company reported $532 million in 2025 revenue, primarily from genomic sequencing services, with pathology AI contributing an undisclosed portion post-acquisition. Public market accountability reduces vendor disappearance risk relative to venture-backed competitors.

The August 2025 Paige acquisition for an undisclosed sum integrated a team of 60 pathology AI engineers and data scientists into Tempus. Leadership continuity is unclear: Paige co-founder Dr. Thomas Fuchs remained through the transition, though his current role at Tempus has not been publicly detailed. Customer references from the Paige era, including Memorial Sloan Kettering and Yale School of Medicine, have not yet issued public statements on Tempus-branded continuity.

The stated roadmap emphasizes cross-platform synergy between tissue-based AI diagnostics and Tempus molecular profiling, aiming to offer oncologists a unified report combining morphology, immunohistochemistry AI scores, and genomic alterations. This vision positions Tempus as a precision oncology data aggregator rather than a standalone pathology tool. Near-term development focuses on expanding biomarker coverage to 150-plus markers by late 2026, though specific additions have not been announced.

How it compares

PathAI offers stronger independent validation, with peer-reviewed studies in Archives of Pathology & Laboratory Medicine and Modern Pathology demonstrating diagnostic concordance rates above 90 percent for specific tumor types. PathAI pricing is similarly opaque but tilts toward per-case fees rather than enterprise contracts, making it accessible to mid-sized pathology groups. Tempus wins on regulatory breadth (CE-IVDR across more modules) and genomic integration, while PathAI wins on published evidence and academic pathologist trust.

Proscia provides a digital pathology platform with modular AI apps, allowing labs to mix third-party algorithms rather than committing to a single vendor's models. Proscia pricing starts at $15,000 per year for small labs (under 10,000 slides annually) with per-slide AI fees beginning at $3 for basic analysis. This transparency and flexibility favor community hospitals, whereas Tempus targets enterprise oncology centers with end-to-end workflows. Proscia lacks FDA clearance for diagnostic use, positioning its tools as research-grade or quality-assurance aids.

Aiforia specializes in research pathology AI with a per-user subscription model ($200 to $400 per pathologist per month) and no per-test fees. This predictable cost structure suits academic institutions running retrospective studies or biomarker discovery projects. Aiforia has CE-IVDR certification for select modules but no FDA clearance, limiting clinical diagnostic use in the United States. Tempus is the better choice for CLIA-certified clinical labs; Aiforia fits translational research teams.

Ibex Medical Analytics focuses on Galen Prostate and Galen Breast, narrow AI tools for Gleason grading and breast cancer subtyping. Ibex holds FDA De Very much breakthrough device designation and CE-IVDR certification, with published validation in European Journal of Cancer. Pricing is per-case (reportedly $40 to $80 per prostate biopsy) with no enterprise minimum. Institutions seeking best-in-class performance for specific tumor types may prefer Ibex, while those wanting pan-cancer breadth choose Tempus.

What clinicians say

No clinician sentiment from Reddit or other indexed forums is available for Tempus Digital Pathology as of May 2026. Zero mentions appear in r/Pathology, r/medicine, or r/OncoPathology discussions over the past 18 months. This silence may reflect the recent August 2025 rebrand from Paige AI, meaning pathologists discussing the platform still reference the legacy name, or it may indicate limited market penetration outside early-adopter academic centers.

The absence of grassroots clinician feedback is notable given that competing tools like PathAI and Proscia generate occasional Reddit threads debating accuracy and workflow integration. Prospective buyers should interpret this gap as a signal to seek direct references from existing Tempus Digital Pathology users rather than relying on organic peer discussion. Vendor-provided case studies from Memorial Sloan Kettering and other institutions may substitute, though these lack the candor of unsolicited clinician commentary.

Pathology departments evaluating the platform should request site visits to current users and ask specific questions about AI override rates, false-positive burdens, and whether the tool measurably reduced turnaround time or diagnostic variability. Without independent clinician voices in the public domain, due diligence becomes more manual and time-intensive.

What the literature says

Zero peer-reviewed publications index Tempus Digital Pathology in PubMed as of May 2026. This evidence gap is striking given the platform's FDA clearances and CE-IVDR certifications, which typically require validation data that subsequently appears in journal form. The August 2025 acquisition may explain the lag: studies conducted under the Paige AI brand have not yet been republished or updated to reflect Tempus branding.

Paige AI, the predecessor platform, generated multiple publications between 2020 and 2024, including studies in Nature Medicine and The Lancet Digital Health demonstrating AI performance on prostate Gleason grading and breast cancer subtyping. Whether these findings transfer to the Tempus-integrated platform remains unclear, as merger-related software changes and dataset shifts can alter model performance. Evidence committees should request Tempus to provide legacy Paige publications and clarify which models remain unchanged.

The absence of current literature limits the ability to assess real-world diagnostic accuracy, false-positive rates, or impact on patient outcomes. Pathologists accustomed to citing peer-reviewed validation when justifying new assays to tumor boards or quality committees will find this gap problematic. Until Tempus publishes updated studies or registries tracking clinical use, adoption requires higher institutional risk tolerance than competitors with active publication pipelines.

Who it's for

Tempus Digital Pathology fits academic medical centers and integrated delivery networks with existing digital pathology infrastructure, annual oncology case volumes above 2,000, and Epic or Cerner EHRs. CMIOs at institutions already using Tempus molecular profiling gain workflow efficiency by consolidating vendors. Pathology departments prioritizing regulatory compliance and seeking the broadest pan-cancer biomarker panel will find this the most defensible choice when facing institutional review boards or compliance audits.

Community hospitals with nascent digital pathology programs and budgets under $100,000 annually should consider PathAI or Proscia instead, as those vendors offer more transparent entry-level pricing and do not require enterprise sales cycles. Solo pathology practices and small group practices lack the slide volume to justify per-test fees and should defer adoption until cost structures shift or consider send-out relationships with reference labs using the platform.

Research-focused institutions conducting translational oncology studies may prefer Aiforia or Proscia, which offer more flexible research-use licensing and easier integration with custom biomarker workflows. Tempus is optimized for clinical diagnostic pathology rather than exploratory research, and its pricing model reflects that priority.

The verdict

Tempus Digital Pathology represents the most regulation-heavy, vendor-stable option in AI pathology as of mid-2026, backed by NASDAQ-listed financial strength and dual FDA/CE-IVDR certifications across 123 biomarkers. This positioning justifies its selection as the AI Pathology silo pick post-acquisition, particularly for institutions where regulatory compliance is the first procurement gate and integration with Tempus genomic services offers strategic value.

The platform's weaknesses are transparency and validation gaps: opaque pricing requiring lengthy enterprise negotiations, minimal independent clinician feedback, zero current peer-reviewed publications, and unresolved questions about which Paige features survived the merger. These are not disqualifying flaws for well-resourced health systems with long procurement timelines, but they demand more intensive due diligence than field-tested alternatives.

Decision rules: If your institution is an academic medical center or large IDN with Epic, annual oncology volumes above 2,000 cases, and existing Tempus molecular contracts, evaluate this first. If you are a community hospital seeking transparent per-slide pricing and faster procurement, choose PathAI or Proscia. If you need peer-reviewed validation to satisfy an evidence committee, wait for Tempus to publish updated studies or select PathAI based on its stronger literature base. If you operate a research lab without clinical diagnostic requirements, Aiforia offers better cost predictability. Early adopters should negotiate contract language that guarantees feature continuity and roadmap transparency through 2027, given post-acquisition uncertainties.